RE:HFS and the CC "Patients who were started on Trogarzo and Egrifta in 2019 40 percent respectively 33 percent were on the drugs after 24 months, in 2022 increasing long term compliance was the key success factor."
This is another symptom of the broader approach leadership had been taking with both patients and investors. Their apporach is purely transactional. Make the sale and move on. Really what they are starting to realize (and is clear to anyone with half a brain) is they need to build and foster ongoing relationships to drive adherence and/or investor sentiment.